Pasar al contenido principal

CHARACTERIZATION OF NEW CHECK-POINTS IN CANCER IMMUNOTHERAPY

PID2020-119567RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Extracellular vesicles from pristane-treated CD38-deficient mice express an antiinflammatory neutrophil protein signature, which reflects the mild lupus severity elicited in these mice

  • Carrillo Rodríguez, Paula
  • Robles-Guirado, José-Ángel
  • Cruz-Palomares, Adrián
  • Palacios-Pedrero, Miguel-Ángel
  • González-Paredes, Elena
  • Más-Ciurana, Alex
  • Franco-Herrera, Carolina
  • Ruiz de Castroviejo Teba, Paloma A.
  • Lario, Antonio
  • Longobardo, Victoria
  • Montosa-Hidalgo, Laura
  • Pérez-Sánchez-Cañete, María M.
  • Corzo Corbera, María-Mercedes
  • Redondo-Sánchez, Sandra
  • Jodar, Ana-Belén
  • Blanco, Francisco J.
  • Zumaquero, Esther
  • Merino, Ramón
  • Sancho, Jaime
  • Zubiaur, Mercedes
In CD38-deficient (Cd38-/-) mice intraperitoneal injection of pristane induces a lupus-like disease, which is milder than that induced in WT mice, showing significant differences in the inflammatory and autoimmune processes triggered by pristane. Extracellular vesicles (EV) are present in all body fluids. Shed by cells, their molecular make-up reflects that of their cell of origin and/or tissue pathological situation. The aim of this study was to analyze the protein composition, protein abundance, and functional clustering of EV released by peritoneal exudate cells (PECs) in the pristane experimental lupus model, to identify predictive or diagnostic biomarkers that might discriminate the autoimmune process in lupus from inflammatory reactions and/or normal physiological processes. In this study, thanks to an extensive proteomic analysis and powerful bioinformatics software, distinct EV subtypes were identified in the peritoneal exudates of pristane-treated mice: 1) small EV enriched in the tetraspanin CD63 and CD9, which are likely of exosomal origin; 2) small EV enriched in CD47 and CD9, which are also enriched in plasma-membrane, membrane-associated proteins, with an ectosomal origin; 3) small EV enriched in keratins, ECM proteins, complement/coagulation proteins, fibrin clot formation proteins, and endopetidase inhibitor proteins. This enrichment may have an inflammation-mediated mesothelial-to-mesenchymal transition origin, representing a protein corona on the surface of peritoneal exudate EV; 4) HDL-enriched lipoprotein particles. Quantitative proteomic analysis allowed us to identify an anti-inflammatory, Annexin A1-enriched pro-resolving, neutrophil protein signature, which was more prominent in EV from pristane-treated Cd38-/- mice, and quantitative differences in the protein cargo of the ECM-enriched EV from Cd38-/- vs WT mice. These differences are likely to be related with the distinct inflammatory outcome shown by Cd38-/- vs WT mice in response to pristane treatment. Our results demonstrate the power of a hypothesis-free and data-driven approach to transform the heterogeneity of the peritoneal exudate EV from pristane-treated mice in valuable information about the relative proportion of different EV in a given sample and to identify potential protein markers specific for the different small EV subtypes, in particular those proteins defining EV involved in the resolution phase of chronic inflammation., Financial support: JS and MZ: Grant SAF-2017-89801-R (Proyecto del plan estatal, Ministerio de Ciencia e Innovación). RM: Grant: PID2020-119567RB-I00. The Proteomic Unit of the IPBLN-CSIC belongs to Proteo-Red-ISCIII (PRB2 and PRB3) and is supported by grants PT13/0001/011 and PT17/0019/0010 CSIC supported in part the article processing charges
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

MYC directly transactivates CR2/CD21, the receptor of the Epstein-Barr virus, enhancing the viral infection of Burkitt lymphoma cells

  • Molina Hoyo, Ester
  • García-Gutiérrez, Lucía
  • Junco, Vanessa
  • Perez-Olivares, Mercedes
  • Yébenes, Virginia G. de
  • Blanco, Rosa
  • Quevedo, Laura
  • Acosta, Juan C.
  • Marín, Ana V.
  • Ulgiati, Daniela
  • Merino, Ramón
  • Delgado, M. Dolores
  • Varela, Ignacio
  • Regueiro, José R.
  • Moreno de Alborán, Ignacio
  • Ramiro, Almudena R.
  • León, Javier
MYC is an oncogenic transcription factor dysregulated in about half of total human tumors. While transcriptomic studies reveal more than 1000 genes regulated by MYC, a much smaller fraction of genes is directly transactivated by MYC. Virtually all Burkitt lymphoma (BL) carry chromosomal translocations involving MYC oncogene. Most endemic BL and a fraction of sporadic BL are associated with Epstein–Barr virus (EBV) infection. The currently accepted mechanism is that EBV is the BL-causing agent inducing MYC translocation. Herein we show that the EBV receptor, CR2 (also called CD21), is a direct MYC target gene. This is based on several pieces of evidence: MYC induces CR2 expression in both proliferating and arrested cells and in the absence of protein synthesis, binds the CR2 promoter and transactivates CR2 in an E-box-dependent manner. Moreover, using mice with conditional MYC ablation we show that MYC induces CR2 in primary B cells. Importantly, modulation of MYC levels directly correlates with EBV’s ability of infection in BL cells. Altogether, in contrast to the widely accepted hypothesis for the correlation between EBV and BL, we propose an alternative hypothesis in which MYC dysregulation could be the first event leading to the subsequent EBV infection., The work was supported by grants PID2020-115903GB-100 to JL and MDD, RTI2018-095673-B-I00 to JRR, PID2019-107551RB-I00 to VG-Y, PID2020-119567RB-I00 to RM, PID2020-117539GB-I00 to IV and PID2019-106773RB-I00 to ARR, all funded by MCIN/AEI/10.13039/501100011033/, Spanish Government, and by “FEDER, Una manera de hacer Europa”, European Union, and by La Caixa HR17-0244 grant to AR. LQ and VJ were recipients of F.P.U. program and Universidad de Cantabria fellowships, respectively. LG-G was a fellow of the Maria Zambrano program, Spanish Government.